Acetaminophen
- Generic Name
- Acetaminophen
- Brand Names
- Acephen, Acetadryl, Allzital, Apadaz, Arthriten Inflammatory Pain, Bupap, Butapap, Cetafen, Children's Silapap, Coricidin Hbp Cold & Flu, Darvocet-N, Dayquil Sinex, Diphen, Dolofin, Dologen, Dologesic Reformulated Jun 2016, Duralgina, Dvorah, Endocet, Esgic, Exaprin, Excedrin, Excedrin PM Triple Action, Excedrin Tension Headache, Feverall, Fioricet, Fioricet With Codeine, Goody's Back & Body Pain Relief, Goody's Body Pain, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Hycet, Legatrin PM, Little Fevers, Lorcet, Lortab, Mapap, Mersyndol, Midol Complete, Midol Cramps & Bodyaches, Nalocet, Norco, Orbivan, Pamprin Max Formula, Pamprin Multi-symptom, Panadol, Pediacare Children's Fever Reducer Pain Reliever, Percocet, Percogesic Reformulated Jan 2011, Pharbetol, Premsyn Pms, Prolate, Rivacocet, Robaxacet, Robaxacet-8, Roxicet, Sudafed PE Sinus Headache, Tactinal, Tencon, Trezix, Triatec, Triatec-30, Triatec-8, Tylenol, Tylenol PM, Tylenol With Codeine, Ultracet, Vanatol, Vanatol S, Vanquish, Xodol, Xolox, Zamicet, Zflex, Zydone
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9NO2
- CAS Number
- 103-90-2
- Unique Ingredient Identifier
- 362O9ITL9D
- Background
Acetaminophen (paracetamol), also commonly known as Tylenol, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the U.S. FDA in 1951 and is available in a var...
- Indication
In general, acetaminophen is used for the treatment of mild to moderate pain and reduction of fever. It is available over the counter in various forms, the most common being oral forms.
...
- Associated Conditions
- Acute Gouty Arthritis, Acute Musculoskeletal Pain, Allergic Reaction, Allergy to Tree Pollen, Ankylosing Spondylitis (AS), Chills, Cold, Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Flu caused by Influenza, Dyskinesia of the Biliary Tract, Dyskinesia of the Urinary Tract, Febrile Convulsions, Febrile Illness Acute, Fever, Fibromyalgia, Flu caused by Influenza, Headache, Joint dislocations, Menstrual Distress (Dysmenorrhea), Mild pain, Muscle Inflammation, Muscle Injuries, Muscle Spasms, Musculoskeletal Pain, Myalgia, Nasal Congestion, Neuropathic Pain, Osteoarthritis (OA), Pain, Postoperative pain, Premenstrual cramps, Rheumatoid Arthritis, Rhinopharyngitis, Rhinorrhoea, Severe Pain, Sinusitis, Spasms, Spastic Pain of the Gastrointestinal Tract, Sprains, Symptoms Cold, Tension Headache, Toothache, Upper Respiratory Tract Infection, Whiplash Syndrome, Acute Torticollis, Articular inflammation, Cold or flu syndrome, Mild to moderate pain, Minor aches and pains, Minor pain, Moderate Pain, Moderate to severe pain
- Associated Therapies
- Airway secretion clearance therapy, Anti-spasmodics, Bronchodilation
FDA Approves Simplified Dosing For Cumberland's Acetadote
The FDA approved a simplified dosing regimen for Cumberland Pharmaceuticals Inc.'s Acetadote, aiming to prevent liver injury from acetaminophen poisoning by combining the first two bags of the standard regimen into a single, slower infusion to reduce medication errors and non-allergic anaphylactoid reactions.
FDA APPROVES ACETADOTE® sNDA
Cumberland Pharmaceuticals announces FDA approval for a simplified dosing regimen of Acetadote, aiming to reduce medication errors and improve patient outcomes in treating acetaminophen poisoning.
Generic Drugs Market To Reach US$ 691 Billion By 2033
The global generic drugs market is projected to grow from USD 424.2 billion in 2023 to USD 691 billion by 2033, driven by patent expirations, cost-effective medications, and chronic disease prevalence. North America led in 2023 with a 38.4% share. Generics offer affordability and are essential for managing chronic conditions, benefiting patients without comprehensive insurance. The market is supported by FDA approvals, collaborations, and advancements in complex generics, despite challenges like patent litigation.
FDA Approves Simplified Dosing Regimen for Acetadote (N-acetylcysteine for injection)
FDA approves simplified dosing regimen for Acetadote, combining first two bags of standard regimen into a single, slower infusion to reduce medication errors and non-allergic anaphylactoid reactions without compromising effectiveness.
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Previously Treated NSCLC
The FDA granted breakthrough therapy designation to sacituzumab tirumotecan (sac-TMT) for treating advanced or metastatic nonsquamous NSCLC with EGFR mutations (exon 19 deletion or exon 21 L858R) that progressed after TKI and platinum-based chemotherapy. This decision is based on phase 2 expansion cohort data from a phase 1/2 study. Sac-TMT is an investigational TROP2-directed ADC, currently undergoing phase 3 trials in various solid tumors, including NSCLC (TroFuse-004 and TroFuse-009).
Related Clinical Trials:
Evaluation of a mobile application to decrease opioid misuse in patients undergoing post-cesarean pain management
A randomized controlled trial at Temple University Hospital evaluated the CPMRx mobile app for post-cesarean pain management. The study, conducted in two phases, involved 100 female patients aged 18-50. Phase I compared the app with electronic monitoring blister packs, while Phase II compared it with hard count methods. The primary outcome was the total number of prescribed opioids used, with secondary outcomes including opioid misuse. The study adhered to CONSORT guidelines and was approved by the institutional review board.
Post-Surgical Pain Treatment Gains FDA Breakthrough Therapy Designation
The FDA granted Breakthrough Therapy Designation to ATX101, a novel bupivacaine and biopolymer configuration for postsurgical pain after total knee arthroplasty. ATX101 aims to provide extended pain relief over weeks, replacing current short-term analgesic products. A phase 2B trial showed ATX101's rapid onset and efficacy comparable to bupivacaine, with reduced opioid consumption and improved function indicators. Allay plans a phase 2B registrational trial in the US.
How Do Medicines Get Their Names?
Medication names are scientifically developed to ensure patient safety, with strict processes including chemical, generic, and brand names. The FDA and international bodies oversee these names to prevent errors and ensure global recognition.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath